Most of the ALS-associated OPTN mutants, but not the POAG-associated mutants, lost the inhibitory effects on TNF-α- and LUBAC-mediated canonical NF-κB activation (Fig. 1). The gene discussed is NFKB1; the disease is amyotrophic lateral sclerosis.